Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

October 23, 2010

Study Completion Date

June 11, 2012

Conditions
Prostate Cancer
Interventions
DRUG

PS 341

PS 341 1.6 mg/m2 IV (in the vein) on days 1 and 8 of each 21 day cycle up to 12 cycles.

DRUG

Docetaxel

Docetaxel 75mg/m2 IV (in the vein) on day 1 of each 21 day cycle up to 12 cycles.

Trial Locations (1)

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

University of Southern California

OTHER

NCT00183937 - Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer | Biotech Hunter | Biotech Hunter